LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer

• DOI: 10.1007/s10620-025-08882-7
• Publication Date: 2025-02-17T22:23:46Z
• Authors: Zhensong Yang; Bin Yu; Jinchen Hu; Lixin Jiang; Mi Jian
• Keywords: Transplant surgery; Cancer Immunotherapy

Leucine-rich repeat containing 25 (LRRC25) is distinguishingly expressed in different tumor types, but the relationship with immune cell infiltration gastric cancer stills unclear. We analyzed LRRC25 expression using pan-cancer data from The Cancer Genome Atlas and gene Gene Expression Omnibus. clinical significance was further evaluated tissues derived trials (no. NCT04208347). Through bioinformatics analysis of TCGA database UCSC Xena database, we found correlation between LRRC15, cancer, infiltration. Further, multiplex immunohistochemistry/immunofluorescence (mIHC/IF), tissue microarray, image acquisition quantitative confirmed our theory. It discovered that highly cancer. Further revealed associated sets implicated immunity, including those innate adaptive chemokine signaling pathways. result (mIHC/IF) suggests a negative relevance response anti-PD-1 treatment reveals trend consistent change on + cells CD16 expression. also significantly level. In particular, there phenotype function NK cells. High contributes to immunosuppressive microenvironment by influencing axis may serve as clinically useful biomarker for predicting neoadjuvant immunotherapeutic patients can affect